Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026)
Intellia Therapeutics (NTLA) reported Income from Continuing Operations of 95327000.0 for Q1 2026, up 15.04% year-over-year from 82863246.4 in Q1 2025, and down 3.35% quarter-over-quarter from 92234000.0 in Q4 2025.
Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Income from Continuing Operations data on file, last reported at 95327000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 95327000.0, up 15.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 394918000.0 (up 20.59% YoY), and the FY2025 annual result was 411795000.0, up 15.35% from the prior year.
- Income from Continuing Operations declined to 95327000.0 in Q1 2026 per NTLA's latest filing, from 92234000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 92234000.0 in Q4 2025 and troughed at 143706000.0 in Q1 2022.
- A 5-year average of 112274058.82 and a median of 104763000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 211.02% in 2022, then surged 30.43% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 104733000.0 in 2022, then fell by 21.67% to 127433000.0 in 2023, then climbed by 1.27% to 125816000.0 in 2024, then gained by 26.69% to 92234000.0 in 2025, then retreated by 3.35% to 95327000.0 in 2026.
- Business Quant data shows NTLA's Income from Continuing Operations at 95327000.0 in Q1 2026, 92234000.0 in Q4 2025, and 104763000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -95.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.33 Mn |
| Dec 31, 2025 | -92.23 Mn |
| Sep 30, 2025 | -104.76 Mn |
| Jun 30, 2025 | -102.59 Mn |
| Mar 31, 2025 | -112.20 Mn |
| Dec 31, 2024 | -125.82 Mn |
| Sep 30, 2024 | -132.65 Mn |
| Jun 30, 2024 | -126.62 Mn |
| Mar 31, 2024 | -101.37 Mn |
| Dec 31, 2023 | -127.43 Mn |
| Sep 30, 2023 | -118.37 Mn |
| Jun 30, 2023 | -119.68 Mn |
| Mar 31, 2023 | -99.98 Mn |
| Dec 31, 2022 | -104.73 Mn |
| Sep 30, 2022 | -103.59 Mn |
| Jun 30, 2022 | -97.60 Mn |
| Mar 31, 2022 | -143.71 Mn |
| Dec 31, 2021 | -79.91 Mn |
| Sep 30, 2021 | -71.64 Mn |
| Jun 30, 2021 | -68.81 Mn |